Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-993 in Diabetic Peripheral Neuropathy
NCT06619860Phase 2Recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Oct 2024
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of VX-993 in diabetic peripheral neuropathy (DPN) (2 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Change From Baseline in the Weekly Average of Daily Pain Intensity on the Numeric Pain Rating Scale at 12 weeks. Started Oct 2024; status: recruiting.
02
Drugs
VX-993
03
Conditions
diabetic peripheral neuropathy (DPN)
Beyond the preview
Go deeper on NCT06619860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06619860.